Your Heart, Your Career, Your Blood Pressure: The Menopause Trifecta

Episode Script

Thanks Toni. We've got a good one today.

Two cardiovascular studies landed this week that I think deserve to be read together, and then there's a Fast Company piece on menopause in the workplace that I want to spend some time on — because it's touching something real even if the advice is a little thin.

Let's start with the JAMA study, because it's the kind of finding that actually shifts how you think about exercise recommendations.

The headline is this: resistance training is associated with lower cardiovascular disease risk in women. And I want to be careful about how I frame that, because the way it gets reported — "lifting weights is good for your heart!" — loses what's actually interesting about the data.

The research suggests this association holds for strength training specifically, distinct from aerobic exercise. We've had decades of "cardio for your heart" messaging. Walk more, get your heart rate up, hit 150 minutes of moderate activity a week. That's all still valid. But the story about resistance work and cardiovascular risk in women has been underdeveloped, and this study in JAMA is part of filling in that picture.

For women in perimenopause and post-menopause, this matters a lot. Estrogen has a protective effect on the cardiovascular system, and as it declines, the risk profile shifts. We know that. What we haven't always had is clear, direct evidence that strength training — not just walking or cycling, but actually loading the muscles — has a specific cardiovascular benefit for women. This study adds weight to that case, and I think it justifies being more direct with women about resistance work as a heart-health tool, not just a bone-density or metabolism tool.

My honest read: the evidence for strength training in this life stage has been building steadily for a few years now, and this is another data point that makes it harder to treat resistance work as optional. If you have a doctor who's telling you to "just walk more" and hasn't mentioned lifting anything heavier than a grocery bag — that conversation is worth having. Bring this study. It's in JAMA; they'll recognize it.

The second study is out in Menopause, which is the NAMS journal, and it's from the UK Biobank — a large, well-regarded cohort — and it looks at premature menopause and hypertension risk. This one deserves more attention than it's getting.

The finding: premature menopause — that's menopause before age 40 — is significantly associated with developing high blood pressure during follow-up. Women who went through premature menopause had a meaningfully higher risk of hypertension than women who didn't. What's interesting is that surgical menopause — having your ovaries removed — did not show the same independent effect once they controlled for other factors.

That distinction matters. It suggests the hypertension risk isn't just about the abrupt hormone drop from surgery. There's something about the biology of premature menopause — possibly the duration of estrogen deprivation over a longer lifespan, or the underlying conditions that can cause it — that drives the cardiovascular risk in a way that surgical menopause doesn't fully replicate.

This has real clinical implications. Women who experience premature menopause are often young enough that cardiovascular risk monitoring gets deprioritized. Your doctor is probably not checking your blood pressure every six months when you're 37 and otherwise healthy-seeming. But if premature menopause significantly shifts your hypertension risk, that monitoring needs to start earlier and happen more consistently than it currently does for most of these women.

The UK Biobank is large enough that I take this finding seriously. It's the kind of evidence that the tools clinicians actually use to evaluate research quality — something like OpenEvidence — would flag as worth incorporating into practice. The question is how long it takes to get from "published in NAMS journal" to "your GP actually knows this." And that gap, historically, has been long.

What I'd want any woman who went through premature menopause — spontaneous, not surgical — to take from this is pretty simple: make sure your blood pressure is being monitored regularly, and make sure whoever's doing it knows your menopause history. Not because this study is definitive, but because the risk signal is real enough that it warrants attention.

The Fast Company piece is a different kind of story, and I want to be honest about its limitations before I say what I think it gets right.

The article is titled "Menopause is burning up senior-level women's careers," and it's framed around four things companies can do to retain women going through menopause. The four things are — and this is a brief summary — flexible work arrangements, training managers, providing access to healthcare, and creating psychological safety to talk about it. Fine. Reasonable. Not exactly revelatory.

What the piece is actually doing, underneath the corporate advice packaging, is documenting something significant: women at the top of their fields, with decades of accumulated expertise and institutional knowledge, are leaving or being pushed out at exactly the moment menopause symptoms hit hardest. Hot flashes in meetings. Brain fog that makes a complex presentation feel impossible. Sleep disruption so severe that functioning at the level expected of a senior executive becomes genuinely difficult. And because the culture still treats menopause as a punchline or a private embarrassment, women are managing it alone, in silence, and deciding it's not worth staying.

That's not a niche wellness problem. That's a workforce issue with real economic consequences, and the fact that it's showing up in Fast Company rather than just health publications tells you something about where the conversation is moving.

My position on the workplace piece is this: the framing is charitable to companies in a way that I think undersells the structural problem. "Here are four things companies can do" implies this is a goodwill question — do companies want to be nice enough to keep these women? But the women leaving aren't junior employees who are easily replaced. They're senior-level, often irreplaceable, and the cost of losing them — in institutional memory, in mentorship, in straight productivity — is enormous. Companies aren't doing women a favor by accommodating menopause. They're protecting their own talent pipeline. The sooner that argument gets made loudly, in business terms, the more traction it'll get with the people who actually make policy.

There's also something worth naming about age discrimination running underneath this. A woman who's visibly struggling with menopause symptoms in a high-pressure environment is navigating that while also knowing she's in an age bracket that's already vulnerable to being managed out. Those pressures don't exist independently. The women described in this article aren't just dealing with hot flashes — they're dealing with hot flashes inside a system that was already making them feel like their time was running out.

That's a harder conversation than "train your managers." But it's the real one.

---

Word count: approximately 1,230 spoken words

---

Sources curated automatically by the Hot Flasher pipeline.